AbstractBySubCategory

Immunotherapy and Biologic Therapy

Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

2011 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Pharmacodynamic and predictive markers of ipilimumab on melanoma patients’ T-cells. J. S. Weber

2503

Phase II cancer vaccination trial with multiple peptides derived from novel oncoantigens against advanced esophageal cancer. K. Kono

2504

Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. M. K. Callahan

2505

Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. H. Okada

2506

Effect of denileukin diftitox on serum GM-CSF and clinical responses in stage IV melanoma. J. Chesney

2507

Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. J. Brody

2509

Phase I clinical trial of cancer vaccine with five novel epitope peptides for patients with metastatic colorectal cancer (mCRC). S. Hazama

2510

A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. J. M. Richards

2511

The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase ll/lll study. M. M. Heiss

2512

Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. H. Oettle

2513

A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors. L. Naumovski

2514

First-in-human trial focusing on the immunologic effects of the survivin-derived multiepitope vaccine EMD640744. S. Gross

2515

A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV). B. Neyns

2519

Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors. M. Simonelli

2521

Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors. G. A. Daniels

2524

Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer. C. R. Heery

2530

A dose confirmation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma. T. K. Eigentler

2531

Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. R. A. Figlin

2532

A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study. H. K. Lyerly

2533

Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells. R. J. Brentjens

2534

A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. L. A. Emens

2535

Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors. P. A. Cohen

2537

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a pharmacodynamic (PD) biomarker in phase I trials of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A). J. Fredrickson

2539

Immunotherapy of advanced melanoma by intratumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand. D. J. Schwartzentruber

2540

Effect of a costimulatory endodomain on the performance of T cells expressing CD19-directed chimeric antigen receptors (CARs) in subjects with relapsed/refractory B-cell malignancies C. A. Ramos

2541

Identification of pre- and post-treatment markers of efficacy in patients with renal cancer treated with MVA-5T4 in a phase III study. R. Harrop

2542

T-cells targeted with anti-CD3 x anti-HER2 bispecific antibody for treatment of women with stage IV breast cancer (phase I): Clinical and immune function results. L. G. Lum

2548

Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. J. P. Connor

2556

Adoptive immunotherapy with autologous CD3/CD28-costimulated T cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. S. J. Schuster

2557

Effect of cellular vaccination of prostate cancer patients on IgG responses to peptide epitopes predicted from prostate tumor–associated autoantigens. G. P. Hemstreet

2558

Clinical effects of Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1-expressing solid tumors as compared to patients with AML/MDS. A. Letsch

2560

A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa). A. K. Patel

2564

Autologous heat shock protein vaccine (HSPPC-96) for patients with recurrent glioblastoma (GBM): Results of a phase II multicenter clinical trial with immunological assessments. A. Parsa

2565

First-in-human phase I study of the antiangiogenic vaccine (OTS11101) targeting VEGFR-1 in patients with solid tumors. H. Hayashi

2568

Pro- versus antitumor effects of bisphosphonate-activated γδ T cells in cancer immunotherapy. V. Kunzmann

2569

The effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM). S. M. Collins

2572

Systemic immune responses induced by intratumoral plasmid IL-12 electroporation in patients with melanoma. E. Cha

2574

Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites. P. Ruf

2575

Population pharmacokinetic (PK) analysis supports fixed dosing for the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. Y. Xin

2586

Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab. J. Jackson

2587

Use of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy to reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and esophagogastric cancer (EGC). R. F. Gabitass

2588

Tumor-targeted cancer vaccination (GeneVieve Protocol): A phase I/II study of intravenous Rexin-G and Reximmune-C for chemotherapy-resistant cancers. J. G. Ignacio

2589

AIDS malignancy consortium (AMC) study 061: A phase I/PK study of sunitinib (S) with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors. J. F. Deeken

2591

A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens. E. P. Hui

2592

Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials. F. G. De Braud

2595

A pilot study of vaccination with sialyl Lewisa (sLea)–keyhole limpet hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21 in metastatic breast cancer patients (pts). A. Diab

2599

The effect of the trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer. H. Reinhard

2601

A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA. R. A. Madan

2604

Enrichment of allogeneic tumor antigen-specific T cells from bone marrow (BM) of patients treated with high-dose post-transplant cyclophoshamide (Cy): A novel approach to adoptive immunotherapy. K. Noonan

2610

A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. L. S. Rosen

2614

Catumaxomab treatment of peritoneal carcinomatosis from EpCAM-positive cancer: Identification of biomarkers with relevance for improved efficacy and survival. M. A. Ströhlein

e13003

A novel concept of adoptive immunotherapy using interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma. M. Ohira

e13006

Immunophenotypic analysis of clinical scale tumor infiltrating lymphocytes generated from a patient with ipilimumab-treated melanoma. M. Donia

e13012

The role of epidermal growth factor receptor (EGFR)-directed recombinant dimeric IgA antibodies in tumor cell killing. T. Valerius

e13014

Differentiation between the EGFR antibodies necitumumab, cetuximab, and panitumumab: Antibody internalization and EGFR degradation. M. B. Topper

e13022

Differentiation between the EGFR antibodies necitumumab (Neci), cetuximab (Cetux), and panitumumab (Pan): Glycosylation and IgE reactivity. D. Yu

e13023

Is the chemoattractant chemerin a natural tumor-suppressive cytokine- R. K. Pachynski

e13025

A UK-based phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens. N. M. Steven

e13028

Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations. M. Petrini

e13029

Differentiation between the EGFR antibodies necitumumab, cetuximab, and panitumumab: In vitro biological and binding activities. B. Saxena

e13030

In vitro antitumor activity of catumaxomab on immune effector cells from Caucasian or Asian (Japanese and Korean) healthy subjects. K. Hasegawa

e13031

Synergistic potentiation of antitumor immunity with light-activated drug therapy and anti-CTLA4 antibody treatment. E. Bromley

e13034

Relationship of Aurora-A kinase and EGFR inhibition in non-small cell lung cancer (NSCLC) cell lines. J. Zhang

e13038

Effective targeting of tumor vasculature with an antibody against tumor endothelial marker 7-R (TEM7R). M. Liu

e13040

Effect of catumaxomab on EpCAM+ tumor cells in vitro in the presence of immune effector cells from ovarian cancer patients treated with chemotherapy. K. Pietzner

e13043

MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. M. S. Block

e13046

Effect of CD3 on the efficacy of TCR gene therapy in vivo. J. W. King

e13047

A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer. N. L. Berinstein

e13050

The effect of NK cell immunotherapy on cancer prognosis through its booster role on cellular (Th1) immunity and its compensator role to maintain the CD4 T-cell subset. S. So

e13051

Hypersensitivity reactions to cetuximab. L. R. Duska

e13054

Evaluation of combination treatment with a BRAF inhibitor (BMS-908662) and CTLA-4 monoclonal antibody in preclinical models. M. Jure-Kunkel

e13055

Catumaxomab administered as a 3-hour intraperitoneal infusion: Results from an integrated safety analysis. B. Schmalfeldt

e13058

Nonclinical safety assessment of a humanized IgG4 anti-SEMA4D antibody to support clinical development. C. A. Cornelius

e13071

Targeting HER2/neu antigen to B cells via CD19 molecule: A vaccine approach for breast cancer immunotherapy. D. Xiang

e13074

Supra-additive effect of IMO-4200, a novel TLR7 and TLR8 dual agonist, with rituximab and cytotoxics in preclinical models of hematologic malignancies. D. Wang

e13076

The effect of intraperitoneal administration of clostridium perfringens enterotoxin on chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice. J. Varughese

e13077

Evaluation of the adverse event of nimotuzumab combined therapy in patients with advanced carcinoma. L. Chen

e13081

Melanoma patients treated with dendritic cell vaccination, interleukin-2, and metronomic cyclophosphamide: Results from a phase II trial. E. Ellebaek

e13084

Gene therapy with tumor-specific promoter mediated suicide gene plus interleukin-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma. Y. Zhou

e13086

Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM). L. M. Krug

TPS139

A phase I study of NPC-1C, a novel therapeutic antibody to treat pancreas and colorectal cancers. N. S. Azad

TPS141

A pilot study of the safety, efficacy, and effects on functional imaging of the combination of cG250 and sunitinib in patients (pts) with advanced renal cell carcinoma (RCC). M. Ciprotti

TPS142